A first-of-its-kind randomized controlled trial found that adding chemoradiation to adjuvant chemotherapy did not improve outcomes in patients with resected gallbladder cancer. The ACCELERATE trial, presented at the Gastrointestinal Cancers Symposium (GICS) 2025, involved 94 patients and showed no significant difference in recurrence-free survival or overall survival between the two treatment groups. While the study had limitations due to early closure and imbalances between treatment arms, it provides valuable data for future research and supports the current standard of care using systemic therapy alone for most patients with resected gallbladder cancer.
In the first randomized controlled trial of its kind, researchers found that adding chemoradiation to adjuvant chemotherapy did not improve outcomes in patients with resected gallbladder cancer . Gastrointestinal Cancers Symposium 2025Although rare, gallbladder cancer has a poor prognosis, with only about 20% of patients surviving 5 years after curative resection, raising the need for more effective treatments.
“This is the first prospective trial to assess adjuvant chemoradiation in resected gallbladder cancer,” said Sharma during his presentation. “We designed this study to answer whether adding chemoradiotherapy to chemotherapy improves recurrence-free survival in this population.”The open-label, multicenter, phase 3 trial randomized 94 patients with resected gallbladder cancer to receive either chemotherapy alone or chemotherapy plus chemoradiation .
In her discussion of the ACCELERATE trial, Namrata Vijayvergia, MD, of the Fox Chase Cancer Center, Philadelphia, who was not involved in the study, praised the researchers for conducting a randomized trial in this rare cancer type. “Doing a randomized trial in gallbladder cancer in a resource-limited setting without support is highly commendable,” she noted. Although gallbladder cancer is rare, its incidence is relatively high in certain regions, including northern India, she added.The study showed that the addition of chemoradiation to adjuvant chemotherapy did not significantly improve recurrence-free survival , which was the primary endpoint of the study.
consulting or advisory fees from Exelixis, RayzeBio, and Taiho Oncology; honoraria from Guidepoint Global; and research funding from Bristol-Myers Squibb/Medarex, ITM Isotope Technologies Munich, Oryzon Genomics, Puma Biotechnology, and Zymeworks.
GALLBLADDER CANCER CHEMORADIATION CHEMOTHERAPY ADJUVANT TREATMENT RECURRENCE-FREE SURVIVAL OVERALL SURVIVAL
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Adding PD-1 Inhibitor to Chemoradiation Boosts Complete Response in Resectable Esophageal CancerThe addition of sintilimab to neoadjuvant chemoradiotherapy achieved a 60% pathological complete response rate vs 47.3% with chemoradiotherapy alone in locally advanced ESCC.
Read more »
More Coventry patients come forward over unnecessary chemotherapySix patients claim they have been given chemotherapy medication temozolomide unnecessarily.
Read more »
Adjuvant Chemotherapy Improves Survival in Resected Pancreatic AdenocarcinomaA retrospective cohort study found that adjuvant chemotherapy, particularly combination regimens like FOLFIRINOX, significantly improves overall survival in patients with resected pancreatic adenocarcinoma after preoperative FOLFIRINOX. Single-agent adjuvant chemotherapy showed no significant survival benefit.
Read more »
Kate Middleton's Private Chemotherapy Journey 'Must Have Been Pretty Lonely,' Royal Insider SaysKate Middleton's chemotherapy treatment 'must have been pretty lonely,' a royal insider tells PEOPLE in this week's exclusive cover story.
Read more »
Adding Radiation to Chemotherapy Doesn't Improve Survival for Locally Advanced Endometrial CancerA new phase 3 trial found that adding radiation therapy to chemotherapy did not improve overall or recurrence-free survival in patients with locally advanced endometrial cancer.
Read more »
Cancer Patient Receives Unnecessary Chemotherapy for 14 YearsA cancer patient in Coventry received unnecessary chemotherapy for more than 14 years, leading to serious health complications. Lawyers representing the patient claim there may be as many as 12 other patients who received similar prolonged and unnecessary treatment. The hospital trust has launched an internal review and apologized for the error. The former consultant involved has been referred to the General Medical Council.
Read more »